Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells
Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells
复制标题
人脐带间充质干细胞治疗重症COVID-19
DOI：
10.1186/s13287-020-01875-5
复制
发表时间：
2020-08-18
影响因子：
7.5
通讯作者：
Feng, Ganzhu
中科院分区：
文献类型：
--
作者：
Shu, Lei;Niu, Changming;Feng, Ganzhu
背景：COVID-19是一种高度传染性的呼吸道疾病。目的：探讨人脐带间充质干细胞输注治疗重症COVID-19的有效性和安全性。方法：将重症COVID-19患者随机分为标准治疗组和标准治疗加hUC-MSC输注组。观察并比较两组患者病情由重症进展为危重症的发生率、28 d病死率、临床症状改善情况、临床症状改善时间、血液学指标包括C反应蛋白、淋巴细胞数、白细胞介素6及影像学改变。hUC-MSC治疗组从重症进展为危重症的发生率和28天死亡率均为0，而对照组中有4例患者恶化为危重症并接受有创通气;其中3例死亡，28天死亡率为10.34%。在hUC-MSC治疗组中，临床改善的时间短于对照组。从干细胞输注的第三天开始，虚弱和疲劳、呼吸急促和低氧饱和度的临床症状明显改善，并在第7天达到显著差异。CRP和IL-6水平从输注的第3天开始显著降低，淋巴细胞计数恢复到正常范围的时间显著更快，并且hUC-MSC组中的肺部炎症吸收在CT成像上显著短于对照组。静脉内移植hUC-MSCs是一种安全有效的方法，可以被认为是严重COVID-1的补救和优先治疗选择。19.
Background: COVID-19 is a highly infectious respiratory disease. No therapeutics have yet been proven effective for treating severe COVID-19.Objectives: To determine whether human umbilical cord mesenchymal stem cell infusion may be effective and safe for the treatment of severe COVID-19.Methods: Patients with severe COVID-19 were randomly divided into 2 groups: the standard treatment group and the standard treatment plus hUC-MSC infusion group. The incidence of progression from severe to critical illness, 28-day mortality, clinical symptom improvement, time to clinical symptom improvement, hematologic indicators including C-reactive protein, lymphocyte number, and interleukin 6, and imaging changes were observed and compared between the two groups.Measurements and main results: The incidence of progression from severe to critical illness and the 28-day mortality rate were 0 in the hUC-MSC treatment group, while 4 patients in the control group deteriorated to critical condition and received invasive ventilation; 3 of them died, and the 28-day mortality rate was 10.34%. In the hUC-MSC treatment group, the time to clinical improvement was shorter than that in the control group. Clinical symptoms of weakness and fatigue, shortness of breath, and low oxygen saturation obviously improved beginning on the third day of stem cell infusion and reached a significant difference on day 7. CRP and IL-6 levels were significantly lower from day 3 of infusion, the time for the lymphocyte count to return to the normal range was significantly faster, and lung inflammation absorption was significantly shorter on CT imaging in the hUC-MSC group than in the control group.Conclusions: Intravenous transplantation of hUC-MSCs is a safe and effective method that can be considered a salvage and priority treatment option for severe COVID-19.